Find clinical trials for Endometrial Cancer in Pittsburgh, PA
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Endometrial Cancer trials near Pittsburgh, PA, USA:
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial...
Phase 2
Pittsburgh, Pennsylvania, United States and 8 other locations
study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial...
Phase 2
Pittsburgh, Pennsylvania, United States and 15 other locations
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune check ...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 20 other locations
study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial...
Phase 2
Pittsburgh, Pennsylvania, United States and 12 other locations
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...
Phase 3
Pittsburgh, Pennsylvania, United States and 242 other locations
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when com...
Phase 3
Pittsburgh, Pennsylvania, United States and 232 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Pittsburgh, Pennsylvania, United States and 202 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
Pittsburgh, Pennsylvania, United States and 168 other locations
to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial...
Phase 2
Pittsburgh, Pennsylvania, United States and 68 other locations
T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors...
Phase 1
Pittsburgh, Pennsylvania, United States and 12 other locations
Clinical trials
Research sites
Resources
Legal